BillionToOne to Present at 44th Annual J.P. Morgan Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Source: Globenewswire
- Conference Participation: BillionToOne will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, from 9:45 AM to 10:25 AM PT, showcasing its innovations in molecular diagnostics.
- Technological Advantage: The company’s patented Quantitative Counting Templates™ (QCT™) molecular counting platform can accurately count DNA molecules at the single-molecule level, enhancing the accuracy and accessibility of molecular diagnostics.
- Investor Relations: A live and archived webcast will be available during the conference, allowing investors to access information through the company’s “Events & Presentations” page, thereby improving investor engagement and transparency.
- Market Positioning: As an emerging molecular diagnostics company, BillionToOne aims to provide powerful and accurate tests to meet the growing market demand, thereby enhancing its influence in the healthcare industry.
Analyst Views on BLLN
About BLLN
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create molecular diagnostics. The Company's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. It applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
